Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs Wellorithm

Two GLP-1 desks, one scoreboard. We put Sprout Health and Wellorithm head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 39 · Grade C

Wellorithm

Visit Wellorithm Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 58 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make Wellorithm a bad call — it's best for readers who specifically want an oral dissolving tablet and will complete an intake before learning any cost. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
40
Supply Reliability
82
70
Transparency
88
28
Access Breadth
92
84
Clinical Oversight
78
40
Track Record
84
58
Sprout HealthBrief Score 86 · 58Wellorithm

Price, coverage & the tracker

Sprout HealthWellorithm
Brief Score86/100 (B)58/100 (C)
Semaglutide$149/moPricing not published
Tirzepatide$199/moPricing not published
CoverageNot disclosed49 states (not Louisiana)
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

Wellorithm: Nothing to track — no price appears anywhere on the public site, and the pricing page 404s.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.